Home / Health / Withings' BeamO Receives FDA Clearance, Revolutionizing Telehealth
Withings' BeamO Receives FDA Clearance, Revolutionizing Telehealth
13 Nov
Summary
- Withings' BeamO device received FDA clearance in 2024
- BeamO can perform ECG, stethoscope, and thermometer tests in under a minute
- Withings offers Cardio Check-Up service to review BeamO results remotely
In November 2024, Withings announced that its innovative medical device BeamO had received clearance from the FDA. BeamO is a multi-function device that can perform an electrocardiogram (ECG), use a stethoscope, and take a temperature reading, all in less than a minute.
Withings unveiled BeamO at the Consumer Electronics Show (CES) in 2024, positioning it as a valuable tool for telehealth. The device comes with a companion app that allows users to send their test results directly to medical professionals. To further enhance the telehealth capabilities, Withings is also offering a Cardio Check-Up service as part of its health subscription. This service enables cardiologists to remotely review the results from BeamO and provide a comprehensive cardiac health assessment to the device owner within 24 hours.
The BeamO device is now available for purchase, retailing at $250. Withings' innovative approach to integrating multiple medical tests into a single, user-friendly device is poised to revolutionize the way people manage their health, especially in the growing telehealth landscape.
